Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

A previous version of this report failed to reflect that the scientific name tirzepatide refers to Zepbound. It has been corrected. A study of two blockbuster weight-loss drugs showed that users ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...